BMC Gastroenterology (Nov 2019)

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

  • Abid T. Javed,
  • Kevin Batte,
  • Mohamed Khalaf,
  • Mustafa Abdul-Hussein,
  • Pooja S. Elias,
  • Donald O. Castell

DOI
https://doi.org/10.1186/s12876-019-1104-z
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Pneumatic dilation (PD) is often billed as a “short term” treatment for achalasia but anecdotally can last years. This study sought to explore how long a single pneumatic dilation may induce symptom remission in a treatment-naïve achalasia patient. Methods A single center, retrospective chart review of patients with an ICD-9 or − 10 code of achalasia between 2005 and 2017 was performed. Treatment naïve patients with manometric diagnosis of primary achalasia were included. Outcomes (success or failure); single vs multiple PD; age; and estimated duration of effect were evaluated. Each patient underwent a single PD unless re-intervention was required for relapse. Results 83 patients (52% female, median 51.6 ± 3.6 years) were included. 43% underwent 2 PD and 13% underwent 3 PD. There was no significant relation between age, gender, and number of PDs. After 1 PD, 87.5% of patients reported > 1 year of symptom remission. 80.5% of relapsed patients reported success after a 2nd dilation. 1 PD was more likely to result in success than multiple PDs (p < 0.001). The measured median duration of remission after 1 PD was 4.23 years, and for 2 PDs, 3.71 years. The median estimated remission time after 1 PD was 8.5 years (CI 7.3–9.7, p = 0.03). Conclusions PD is a safe, durable treatment for achalasia. A single PD is likely to last years. A second PD, if required, also has a high likelihood of success.

Keywords